Bbi-214 |top|

Bi-214 is part of the uranium-238 decay series and is a daughter product of lead-214 (Pb-214).

When a person with Celiac disease consumes gluten, their immune system mounts an attack on the small intestine. A key marker for this disease is elevated levels of —specifically, anti-tissue transglutaminase antibodies and anti-gliadin antibodies. bbi-214

The challenge for BioLineRx has been delivery. As a protein-based enzyme, BBI-214 must survive the harsh acidic environment of the stomach to reach the small intestine, often requiring enteric-coated formulations or specific delivery vehicles to ensure bioavailability. Bi-214 is part of the uranium-238 decay series

This mechanism differs fundamentally from other approaches in the pipeline. Drugs like latiglutenase aim to digest the gluten in the stomach before it reaches the intestine. BBI-214, however, operates at the immunological level, acting as a cleanup crew for the immune complexes that have already formed. The challenge for BioLineRx has been delivery

: The Bell 214 is a medium-lift helicopter. Technical manuals (e.g., BHT-214B-MM-1) cover maintenance and airworthiness limitations for these models.

Despite the promise, BBI-214 faces hurdles: